Bavarian Nordic Announces Changes in Management

Bavarian Nordic Announces Changes in Management

KVISTGAARD, Denmark, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S
(OMX:BAVA) today announced that Reiner Laus, Executive Vice President and
Division President Cancer Vaccines will leave his position effective as of

Reiner Laus has headed Bavarian Nordic's California-based cancer vaccine
division, BN ImmunoTherapeutics since 2005, where it was founded to develop
active immunotherapies within the cancer field based on the company's MVA-BN®
technology. During his tenure, Dr. Laus has been instrumental in the
development of the company's clinical pipeline, including the preparations for
the current late-stage clinical development of PROSTVAC®. The company has
initiated a search for a replacement to fill his position which is expected to
be concluded soon.

About Bavarian Nordic

Bavarian Nordic is a vaccine-focused biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline targets
cancer and infectious diseases, and includes ten development programs. In
oncology, the company's lead program is PROSTVAC®, a therapeutic vaccine
candidate for advanced prostate cancer that is the subject of an ongoing
pivotal Phase 3 trial and is being developed under a collaboration agreement
with the National Cancer Institute. In clinical Phase 1 and Phase 2 trials,
PROSTVAC® has been tested in nearly 600 patients. In infectious diseases, the
company's lead program is IMVAMUNE®, a non-replicating smallpox vaccine
candidate that is being developed and supplied for emergency use to the U.S.
Strategic National Stockpile under a contract with the U.S. Government. For
more information, visit

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or
other information that is not historical information. We undertake no
obligation to publicly update or revise forward-looking statements to reflect
subsequent events or circumstances after the date made, except as required by

Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
Press spacebar to pause and continue. Press esc to stop.